Pα+ Psychedelic Bulletin #176: Drug Developers Discuss Trial Design; Massachusetts Vote is Too Close to Call as Last-Minute Donations Flow In; SEC Charges ‘Pump and Dump’ Scheme

Speaking at TD Cowen’s September 26th panel, Advancement in Psychedelic Therapies for Neuropsychiatry, execs from atai Life Sciences, Cybin, and GH Research fielded questions on Lykos’ new drug application (NDA), psychedelic trial design, and the broader field of psychedelic candidates. A substantial portion of the panel discussion was dedicated to discussing Lykos Therapeutics’ recent…

Source